Recent
price
P/E
ratio
div
yld
1.56%
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Breakfast News: Summit’s FDA Setback Isn’t the End
Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
AstraZeneca cuts 600 sales jobs in US, Bloomberg News reports
EU panel backs AstraZeneca hypertension drug baxdrostat
AlphaCore Capital LLC Buys 3,357 Shares of AstraZeneca Plc $AZN
AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
Omniose Announces Its Acquisition by AstraZeneca
7,250 Shares of AstraZeneca Plc $AZN Purchased by CenterBook Partners LP
AstraZeneca Plc $AZN Stock: Ethic Inc. Grows Holdings
AstraZeneca Plc (NYSE:AZN) Stock Has Average Price Target of $206.67 According to Brokerages
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
27,056 AstraZeneca Plc $AZN Shares Acquired by International Assets Investment Management LLC
1,929,102 Shares of AstraZeneca Plc $AZN Acquired by Bank Julius Baer & Co. Ltd Zurich
AstraZeneca: 3 Key Takeaways for Long-Term Investors
AstraZeneca (NYSE:AZN) Share Price Crosses Above 200 Day Moving Average – Time to Sell?
AstraZeneca Plc $AZN Shares Acquired by Brian Low Financial Group LLC
Already premium?